Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States & Sanofi

19 shared events · Importance 4 · Last updated Sep 22, 2026

Importance
4
Shared Events
19
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
69
Business
United States: The US is part of North America, which held the largest market share in 2025, supported by strong regulatory frameworks and advanced manufacturing.
Sanofi: Sanofi is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
53
Regulatory
United States: Cited as a key competitor attracting far more pharmaceutical investment, with healthcare spending at about 2% of GDP versus Europe's 1%. Its more aggressive policies are said to be drawing capital and launches away from Europe.
Sanofi: A signatory of the open letter calling on the European Union to boost pharmaceutical investment. The appeal reflects its concern about Europe lagging the United States and China in drug research and trials.
Sep 22, 2026 · 6 articles
49
Regulatory
United States: The U.S. gains a new flu vaccine option, potentially improving public health outcomes for older adults.
Sanofi: Sanofi's high-dose flu vaccine served as a comparator in trials; the new mRNA vaccine may compete with its products.
Aug 05, 2026 · 105 articles
37
Business
United States: The United States is the regulatory and market jurisdiction for the IPO, with the SEC and Nasdaq based there.
Sanofi: Sanofi participated in a concurrent private placement, purchasing 500,000 shares for $7.5 million, and has a prior $1.5 billion research collaboration with Scribe. This deepens Sanofi's strategic involvement in gene editing and cardiovascular therapies.
Jul 06, 2026 · 25 articles
35
Regulatory
United States: A target market for future regulatory approval and collaborations, representing a significant growth opportunity for Pulse.
Sanofi: Already a customer of Pulse's manufacturing, the approval may strengthen their supply relationship.
Aug 20, 2026 · 6 articles
28
Business
United States: The US approved Awiqli earlier in 2026, contributing to its global rollout.
Sanofi: Sanofi's Lantus faces new competition from Awiqli, which offers less frequent dosing and lower cost per unit.
Jul 09, 2026 · 21 articles
24
Business
United States: The United States is a key market for Tezspire, where eosinophilic esophagitis affects over 470,000 people. The trial success could lead to expanded approval and market access.
Sanofi: Sanofi's Dupixent competes with Tezspire in severe asthma and potentially in eosinophilic esophagitis. Tezspire's success could increase competitive pressure on Dupixent.
Aug 27, 2026 · 6 articles
19
Business
United States: Key market where FDA approvals and Nasdaq-listed ADRs for the share consideration shape the deal's milestone structure and investor access.
Sanofi: Named among recent radiopharmaceutical acquirers, underscoring competitive pressure in the sector that motivates Telix's vertical integration.
Sep 21, 2026 · 6 articles
16
Tech
United States: Obesity epidemic in children drives demand for treatments; policy implications.
Sanofi: Segev received honoraria; unrelated to study.
Sep 04, 2026 · 7 articles
10
Business
United States: Regulatory jurisdiction where FDA designations were granted and where commercialization rights are included.
Sanofi: Mentioned as a collaborator with Innate, not directly involved in this partnership.
Aug 10, 2026 · 10 articles
5
Business
United States: The United States hosts Alkermes' corporate office, R&D center in Massachusetts and manufacturing facility in Ohio, mentioned as background.
Sanofi: Sanofi is a former employer of Whitaker, mentioned only as background.
Sep 16, 2026 · 7 articles
0
Regulatory
Dec 19, 2025 · 7 articles
0
Business
Feb 24, 2026 · 8 articles
0
Domestic
Sanofi: Sanofi is a major insulin maker that has moved to cut the cost of insulin and offers a savings program for people without health insurance.
Apr 02, 2026 · 6 articles
0
Regulatory
Sanofi: Sanofi is mentioned as a collaborator with Innate Pharma in immuno-oncology.
Apr 02, 2026 · 7 articles
0
Domestic
Mar 16, 2026 · 22 articles
0
Business
Sanofi: Sanofi, in collaboration with Regeneron Pharmaceuticals, developed Dupixent and received International — European Commission approval for its use in treating chronic spontaneous urticaria in young children, which is expected to boost its market position and revenue.
Apr 13, 2026 · 8 articles
0
Regulatory
Sanofi: Sanofi is mentioned as a biopharmaceutical company with whom Innate Pharma has established collaborations.
Apr 13, 2026 · 6 articles
0
Regulatory
May 15, 2026 · 17 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States and Sanofi interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.